跳至主要内容
临床试验/NCT06601010
NCT06601010招募中不适用

The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.

Ruijin Hospital1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2024年9月24日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
30
试验地点
1
主要终点
Evaluation the responses to immunotherapy of pancreatic cancer

研究概览

简要总结

This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for pancreatic cancer.

详细描述

The investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. All participants will undergo a 68Ga-grazytracer PET/CT after 3 cycles of immunotherapy to evaluate response. The imaging response measurements will be compared with the histopathological or clinical assessment results as gold standard.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Pathological diagnosis of pancreatic cancer requiring combination immunotherapy after evaluation according to clinical guidelines
  • Signed and dated informed consent form
  • Commitment to comply with research procedures and co-operation in the implementation of the full research process 4 .aged 18-75 years old 5 .The patient is in good general condition with an expected survival of > 6 months

排除标准

  • Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc.
  • Intestinal perforation, complete intestinal obstruction
  • Pregnant women and women who may be pregnant, women who are breastfeeding.
  • Non-compliant person

结局指标

主要结局

Evaluation the responses to immunotherapy of pancreatic cancer

时间窗: up to about 10 weeks

The value of 68Ga-grazytracer PET in monitoring responses to immunotherapy of pancreatic cancer

Standardized uptake value(SUV)

时间窗: up to about 10 weeks

SUV of 68Ga-grazytracer uptake on PET/CT images for tumor lesions

Target-to-background ratio(TBR)

时间窗: up to about 10 weeks

68Ga-grazytracer uptake ratio of tumor lesions to mediastinum and liver blood pool on PET/CT images.

次要结局

  • Progress free survival(1 years)
  • Overall survival(1 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Hu Jiajia

Deputy director

Ruijin Hospital

研究点 (1)

Loading locations...

相似试验

The Value of 68Ga-grazytracer PET in Monitoring... | 临床试验